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Sir, 17 
 18 
Meropenem has good tissue penetration and broad-spectrum bactericidal activity.  Often 19 
employed to treat multi-resistant Gram-negative organisms, meropenem was active against 20 
98.7% of 1657 clinical surveillance Enterobacteriaceae isolates collected in the United 21 
States in 2005.1  Its stability permits combination with polymethylmethacrylate (PMMA) bone 22 
cement.  We present here the first published account of the use of meropenem-loaded 23 
PMMA in human prosthetic joint infection.   24 
  25 
The patient, a 66 year-old with insulin-requiring type 2 diabetes, polymyalgia rheumatica 26 
(treated with 10mg prednisolone daily) and nodular prurigo, kindly gave written informed 27 
consent to publication.  She was 170cm tall and weighed 102kg.  She had had her left hip 28 
replaced for osteoarthritis at another institution in 1996.  This prosthesis had functioned 29 
excellently for over 10 years before becoming unstable; cup revision in September 2006 was 30 
complicated by formation of an infected haematoma.  The joint was replaced again in 31 
October 2006 and the patient put on a long antibiotic course.  Recurrent dislocation led to 32 
further socket revision in July 2007.  The patient was referred to our specialist hip revision 33 
service with continuing instability in late 2008.  On 17th February 2009, both components 34 
were revised.  Seven operative tissue specimens were sterile. Antibiotic prophylaxis was 35 
with 48 hours of vancomycin and gentamicin. 36 
 37 
Post-operatively she developed a wound haematoma.  The wound started to discharge and 38 
she returned to theatre on 10th March for a washout; the components were retained and the 39 
wound closed. Five of five tissue specimens grew Klebsiella pneumoniae susceptible to co-40 
amoxiclav, cefotaxime, piptazobactam, carbapenems, ciprofloxacin, amikacin and 41 
trimethoprim, but resistant to amoxicillin and gentamicin.  Intravenous co-amoxiclav 1.2g 42 
thrice daily was administered from 10th to 27th March, followed by oral co-amoxiclav 625mg 43 
thrice daily until 20th April. 44 
 45 
Infection persisted, and extensive osteomyelitis developed in the proximal femur. A decision 46 
was made to proceed to one-stage revision.  Both joint components and the proximal femur 47 
were replaced on 21st April.  One of three acetabular specimens grew K. pneumoniae 48 
(susceptibilities as above), while two of three grew Morganella morganii susceptible to the 49 
cephalosporins, piptazobactam, carbapenems, ciprofloxacin, amikacin and gentamicin, and 50 
resistant to co-amoxiclav, colistin and trimethoprim.  From 24th April through 12th May the 51 
patient received 1.2g co-amoxiclav intravenously thrice daily. 52 
 53 
On 12th May, a large abscess connected superficial and deep tissues.  This was washed out.  54 
The acetabular component was removed.  10g meropenem was crushed in a sterile vacuum 55 
mixing bowl (Optivac® Fusion™, Biomet, Bridgend); two 40g mixes of sterile orthopaedic 56 
bone cement (Palacos, Biomet; each mix containing 1.8g gentamicin and 1.8g clindamycin 57 
preloaded by the manufacturer) were added.  The resulting cement was used to fix the 58 
replacement acetabular prosthesis.  A third cement mix combined with 5g meropenem was 59 
used to coat the stem.  Intravenous meropenem and amikacin and serial vac dressings were 60 
initiated.  Samples of pus, fluid and hip tissue each grew scant K. pneumoniae susceptible to 61 
ciprofloxacin, cephalosporins, ertapenem and meropenem but resistant to co-amoxiclav, 62 
piptazobactam, gentamicin and amikacin.   63 
 64 
On 13th May, drain fluid was collected.  An ISO susceptibility test agar plate was seeded with 65 
the patient’s K. pneumoniae isolate; a second plate was seeded with fully susceptible 66 
Escherichia coli strain ATCC 25922.  20µL of drain fluid was placed at the centre of each 67 
plate.  Plates were incubated aerobically at 36°C for 18 hours.  Inhibition zones suggested 68 
that antibacterial activity in the vicinity of the prosthesis was sufficient to inhibit growth of the 69 
patient’s K. pneumoniae (and therefore also her more susceptible M. morganii).   70 
 71 
An aliquot of 13th May drain fluid was sent to the UK Antimicrobial Reference Laboratory, 72 
Bristol, where its meropenem concentration was measured (by high performance liquid 73 
chromatography) at 73.5mg/L.  Drug levels in pre- and post-meropenem-dose serum 74 
samples (also collected on 13th May) were considerably lower (9.3mg/L and 12.5mg/L 75 
respectively), suggesting that meropenem was eluting from the cement.  The accepted 76 
meropenem susceptibility breakpoint is 4mg/L.2 77 
 78 
The patient received intravenous meropenem 1g thrice daily until 30th July, with intravenous 79 
amikacin 1g daily for the first two postoperative weeks.  By 30th July, she was well and 80 
mobilising, and was discharged home off antibiotics. 81 
 82 
Antibiotic loading of PMMA is routine practice in joints with suspected or proven infection.  83 
The aim is to achieve high antibiotic levels at the site of infection while minimising systemic 84 
toxicity.  The antibiotic used must be heat stable (since cement polymerisation is strongly 85 
exothermic) and water soluble (to allow diffusion from cement to tissues).  The most 86 
common antibiotics used are gentamicin, vancomycin, and cefazolin, either alone or in 87 
combination.3  Unfortunately, this patient’s Klebsiella isolate was gentamicin-resistant, 88 
cefazolin is not available in the UK, and other cephalosporins are not heat stable.  Previous 89 
studies have suggested that meropenem elutes from small PMMA discs in vitro,4-5 but the 90 
present report is the first to provide useful in vivo data.  Meropenem should be considered 91 
for inclusion in bone cement in patients with difficult-to-treat prosthetic joint infections. 92 
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